BackAmphastar Pharmaceuticals Overview
Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Target Price

Where could AMPH trade next? Consensus target price: $23.

Get informed when a big investor buys or sells

+ Follow

Share Price

$25.14

Average Target Price

$23.008.5% downside

1 analysts in the last 4 months

High: $23 | Low: $23

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-18Barclays$238.5% downsideOpen
2026-06-03Barclays$2020.4% downsideOpen
2026-05-14Wells FargoBenjamin Burnett$1924.4% downsideOpen
2026-05-11Piper Sandler$2116.5% downsideOpen
2026-04-20JefferiesDennis Ding$2212.5% downsideOpen
2025-12-08Barclays$3019.3% upsideOpen
2025-03-21Piper SandlerDavid Amsellem$3227.3% upsideOpen
2024-08-08Piper SandlerDavid Amsellem$66162.5% upsideOpen
2024-05-23Piper SandlerDavid Amsellem$71182.4% upsideOpen
2022-03-12Piper SandlerDavid Amsellem$3539.2% upsideOpen

Amphastar Pharmaceuticals (AMPH) FAQ

Amphastar Pharmaceuticals (AMPH) currently reports a target price of $23. Use the charts on this page to explore Amphastar Pharmaceuticals's target price history and peer comparisons.

Analysts' average 12-month price target for Amphastar Pharmaceuticals is $23, about 8.5% downside from the current share price of $25.14. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $23, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Amphastar Pharmaceuticals, and consider following AMPH for alerts when major investors trade the stock.

Amphastar Pharmaceuticals is classified in the Healthcare sector. On target price, it currently shows $23. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AMPH with unrelated industries.